Tarsa Therapeutics, Inc. — Form D

Tarsa Therapeutics, Inc. of PHILADELPHIA, PA, a company, filed a Form D exempt-offering notice with the SEC on 2017-07-24. The offering totals $1.0M, of which $550K was reported sold. Industry: Biotechnology.

Offering

Filed: 2017-07-24
Form: D
Accession: 0001475030-17-000002
Industry: Biotechnology
Exemptions: 06b
Total offering: $1.0M
Amount sold: $550K
Remaining: $450K
Investors: 3
Date of first sale: 2017-07-07
Security types: debt
Revenue range: Decline to Disclose
SEC file number: 021-291370

Issuer

Name: Tarsa Therapeutics, Inc.
CIK: 0001475030
Entity type: Corporation
Jurisdiction: DELAWARE
Incorporated: 2009
Address: 8 PENN CENTER, PHILADELPHIA, PA, 19103
Phone: 267-273-7940

Officers, directors & promoters (12)

Name	Role	Location
Eric Bednarski	Director	Boston, MA
David Brand	Director	San Francisco, CA
Martin Edwards	Director	Boston, MA
RICHARD KOLLENDER	Director	LOWELL, MA
Richard Levy	Director	Chicago, IL
David Brand	Executive Officer	San Francisco, CA
Gregory Lumpkin	Executive Officer	Philadelphia, PA
Derek Ferguson	Director	New York, NY
James Tananbaum	Director	South San Francisco, CA
Lewis Geffen	Executive Officer	Cambridge, MA
Ashleigh Palmer	Director	Waltham, MA
Matthew Rieke	Director	Philadelphia, PA

Other filings by this issuer (7)

Filed	Form	Offering	Sold
2017-01-13	D	$1.6M	$1.6M
2016-07-14	D	$1.3M	$1.3M
2016-02-19	D	$2.0M	$2.0M
2012-03-22	D	$28.0M	$13.8M
2011-04-21	D/A	$24.5M	$15.5M
2010-10-08	D	$8.5M	$3.5M
2009-10-27	D	$24.1M	$12.1M

More